Aphexda is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade One dosage of Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal of ≥ 6 million…Original Article
FDA Approves Aphexda (motixafortide) to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
